Mantle Cell Lymphoma

While chemotherapy is widely used in the frontline treatment of mantle cell lymphoma (MCL), earlier use of BTK inhibitors such as Imbruvica (ibrutinib) may soon make chemotherapy obsolete for some patients, according to new data presented at the 2019 American Society of Hematology (ASH) Annual Meeting.

The Food and Drug Administration approved Brukinsa to treat relapsed and refractory mantle cell lymphoma, but what does this mean for patients?

While resistance can often make it a challenge to treat mantle cell lymphoma, therapies have come a long way in recent years thanks to the emergence of personalized treatment and the use of BTK inhibitors, according to one expert.

Researchers are expanding a clinical trial to include more patients with mantle cell lymphoma after some patients given the combination of medications under investigation showed no signs of cancer after treatment.

The Food and Drug Administration has approved Brukinsa to treat patients with mantle cell lymphoma whose disease has stopped responding to other medications or has recurred.

Dr. Thomas Weber has died following a ‘short but fierce’ fight with mantle cell lymphoma.

Patients and survivors shared messages of hope and enjoyed an evening of fun at the 11^th annual celebration sponsored by Hackensack Meridian Health. 

Having a parent, sibling or child with blood cancer raises an individual’s risk of also receiving a blood cancer diagnosis, according to the results of a large European study.

While emerging therapies for mantle cell lymphoma (MCL) continue to shape the treatment landscape, no key standard currently exists, says one expert – particularly for older patients, who benefit most from a treatment approach that has been tailored to fit them and their disease.

BTK inhibitors and CAR-T cell therapies for mantle cell lymphoma help to expand the treatment landscape for patients.